Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer.
In Hee LeeSoo Jung LeeByeongju KangJeeyeon LeeJin Hyang JungHo Yong ParkJi-Young ParkNora Jee-Young ParkEun Ae KimJieun KangYee Soo ChaePublished in: Breast cancer research and treatment (2024)
We found that MELK acts downstream of Del-1 and is a promising druggable target, especially in basal-like and mesenchymal stem-like subtype.
Keyphrases